Pliant Therapeutics, Inc. (PLRX) — 10-Q Filings
All 10-Q filings from Pliant Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
PLRX Narrows Losses Amid R&D Cuts After Bexotegrast Failure
— Nov 6, 2025 Risk: high
Pliant Therapeutics, Inc. (PLRX) reported a net loss of $26.301 million for the three months ended September 30, 2025, a significant improvement from the $57.76 -
Pliant's Q2 Loss Widens to $49.7M Amid R&D Surge
— Aug 7, 2025 Risk: high
Pliant Therapeutics, Inc. reported a net loss of $49.7 million for the three months ended June 30, 2025, a significant increase from the $38.2 million net loss -
Pliant Therapeutics Files Q1 2025 10-Q
— May 8, 2025 Risk: low
Pliant Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial position and operational activities. K -
Pliant Therapeutics Files Q3 2024 10-Q
— Nov 7, 2024 Risk: medium
Pliant Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its busine -
Pliant Therapeutics Files Q2 2024 10-Q
— Aug 7, 2024 Risk: medium
Pliant Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second qu -
Pliant Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
— May 6, 2024 Risk: low
PLIANT THERAPEUTICS, INC. (PLRX) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. Pliant Therapeutics, Inc. filed a 10-Q report for the period endin
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX